Company Overview
DM Bio (Dong-A Meiji Bio) is a biopharmaceutical company specializing in the development and manufacturing of mammalian cell culture based therapeutic proteins and monoclonal antibodies. Located within the Incheon Songdo biocluster, DM Bio developed as a joint venture between Dong-A Socio Holdings and Meiji Seika Pharma, which both have long histories in the pharmaceutical industry of Korea and Japan, respectively. Since its first manufacture in 2015, DM Bio dedicates itself to matching specific demands of global biotechnology companies with highly qualified experts and state-of-the-art manufacturing facilities.

CDMO Service
We accelerate product success for our customers by providing:
- Process development: cell culture (up to 200L), purification, process characterization, scale-up studies, technology transfer
- cGMP manufacturing: 8,000L total capacity, cell culture (up to 2,500L) and purification of mAbs, proteins, and biosimilars, technical batches, analytics, regulatory support
- Aseptic fill & finish: aseptic filling of PFS for clinical and commercial products, blister and carton packaging, technical batches, batch release testing, regulatory support

Pipeline
We are actively seeking partnerships to out-license or co-develop our pipelines listed below:
- Ustekinumab biosimilar (trade name Stelara)
- Trastuzumab biosimilar (trade name Herceptin)
- Darbepoetin alfa biosimilar (trade name Aranesp)